Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is a newly defined entity and recent studies have suggested a decrease of a few percentage points in the rate of malignancy (ROM) for the positive-for-malignancy (PFM) cytology category as a result of NIFTP implementation. However, the distinction between a diagnosis of PFM and one of suspicious for malignancy (SFM) may depend on a variety of factors. In the current study, the authors investigated the ROM for the PFM and SFM diagnoses before and after histologic NIFTP reclassification.
INTRODUCTION
The much anticipated landmark study regarding the nomenclature revision for the encapsulated follicular variant of papillary thyroid carcinoma (FVPTC) was published in electronic form in April 2016. 1 This document detailed the clinicopathologic and molecular features of a subset of encapsulated FVPTCs that are expected to demonstrate a very indolent clinical course when treated with lobectomy alone (without radioactive iodine treatment) because the constituent neoplastic cells are considered to represent an in situ or dysplastic-like process ( but not yet malignant). The new entity, called "noninvasive follicular thyroid neoplasm with papillarylike nuclear features" (NIFTP) is approximately equivalent to noninvasive encapsulated FVPTC; however, the specific diagnostic criteria for inclusion in the document are elaborate and not all noninvasive encapsulated FVPTCs qualify as NIFTPs (Table 1) . 1 Even before the inception of the term NIFTP, interest in the potential impact of the reclassification of noninvasive encapsulated FVPTC as a nonmalignant, yet not entirely benign, entity was high. Strickland et al 2 and
Faquin et al 3 studied the effect of reclassification on the rate of malignancy (ROM) associated with each of The Bethesda System for Reporting Thyroid Cytopathology (BSRTC) diagnoses. 4 These and other similar studies predicted a drop of a few percentage points in ROM for the positive for malignancy (PFM) category and a larger drop for the suspicious for malignancy (SFM) category. 5 Conversely, another study by Ibrahim and Wu examined the resected noninvasive encapsulated FVPTC cases and reported no presurgical cytology diagnosis of PFM. 6 After inception of the NIFTP term, Maletta et al performed a similar study and found a presurgical cytology diagnosis of PFM in 2% of NIFTP cases. 7 For liquid-based cytology specimens, Bizzarro et al demonstrated that reclassified NIFTP cases had a prior cytology diagnosis of PFM in 4 of 37 cases (10.8%). 8 More recently, Brandler et al 9 and
Yang et al 10 reported that 7.1% and 5.6% of cases, respectively, reclassified as NIFTP had a presurgical cytology diagnosis of PFM. It is interesting to note that Brandler et al performed a blinded reexamination of the 4 cytology cases corresponding to the reclassified NIFTP cases and found that 3 of these cases were downgraded to indeterminate categories: 1 as follicular neoplasm/suspicious for follicular neoplasm and 2 as SFM. 9 The explanation for this shift was that the cytopathologists had become aware of the possibility of NIFTP as a nonmalignant outcome. These studies demonstrated that the reported drop in ROM due to reclassification varied from institution to institution and suggested that it may be influenced in part by the cytopathologist's perspective on the false-positive diagnosis.
From a clinical point of view, the degree of the drop in the ROM for the PFM diagnosis can be concerning; a drop of a few percentage points from the high 90s to the low 90s potentially undermines clinical confidence in the PFM diagnosis. Recognition of factors that influence the ROM would help cytopathology laboratories adjust to NIFTP implementation. In the current large study, we examined changes in the ROM after retrospective NIFTP reclassification and searched for underlying factors.
MATERIALS AND METHODS
The current study was approved by the University of Pittsburgh Institutional Review Board. Cases enrolled in this study were thyroid cytology cases that dated from September 2008 to September 2016. Thyroid fine-needle aspiration (FNA) was performed under ultrasound guidance by a radiologist or endocrinologist and samples were collected using a 23-gauge, 25-gauge, or 27-gauge needle. On-site cytologic evaluations were performed at the request of the radiologist or endocrinologist. Although the number of were identified from files at the University of Pittsburgh Medical Center (UPMC)-Presbyterian. Of these, all thyroid cytology cases with surgical pathology resection follow-up were examined. After excluding noninvasive encapsulated FVPTC cases measuring 1 cm that were considered for NIFTP reclassification, the remaining cases with cytology and surgical pathology correlates constituted the core group of cases for the current study. Cytology cases were diagnosed according to the stated criteria and reporting format of the BSRTC. 4 During the period of the current study, cytology cases were signed out by 5 to 7 board-certified cytopathologists (the number of available pathologists varied from year to year). An ad hoc survey of 5 cytopathologists who have been in the study system for the period of the study was conducted to query which of the 6 BSRTC criteria for PTC (enlarged nuclei, oval or irregularly shaped and sometimes molded nuclei, longitudinal nuclear grooves, intranuclear cytoplasmic pseudoinclusions, pale nuclei with powdery chromatin, and marginally placed micronucleoli) were required to make a definitive diagnosis of PFM. Furthermore, to test the use of BSRTC criteria, 20 random PFM cases and 20 random SFM cases were blindly reviewed for the presence of each criterion by an author who specializes in cytopathology (N.P.O.).
Cytologic-histologic correlation was performed with subtyping of the malignant neoplasms. Resected cases of noninvasive encapsulated FVPTC measuring >1 cm were reexamined for the possibility of NIFTP reclassification according to the recently stated criteria. 1 ROMs before and after NIFTP reclassification (as a nonmalignant diagnosis) were calculated for the PFM and SFM cytology diagnostic categories. Molecular testing was performed on select cases and these results were correlated with the SFM and PFM diagnoses before and after NIFTP reclassification. The molecular profiles of cases reclassified as NIFTP also were compiled. The Fisher exact test was used for statistical calculations (https://graphpad.com/quickcalcs/contingency1. cfm).
RESULTS
For the study period, a total of 338 PFM and 137 SFM cases with surgical resection correlation were identified. PFM and SFM cases represented 3.8% and 1.6%, respectively, of the total number of thyroid cytology cases. Overall, approximately 75.6% of the patients with PFM cases and 74.3% of the patients with SFM cases underwent thyroid surgical resection at UPMC-Presbyterian. Because UPMC is a multihospital health care system, some patients may have had thyroid cytology specimens acquired at UPMC-Presbyterian but received follow-up treatments at one of the other UPMC hospitals or at an outside institution. For the purposes of the current study, only those patients who underwent surgical resection at UPMCPresbyterian were included. Before reclassification of noninvasive encapsulated FVPTC to NIFTP, 336 PFM cases (ROM, 99.4%) demonstrated a malignant resection outcome ( Fig. 1) ( Table  2 ). The 2 false-positive cytology cases were 1 case of hyalinizing trabecular tumor and 1 case of nodular hyperplasia. These cases had been identified before this report through our quality assurance (QA) program. Three cases with the reported histologic outcome of noninvasive encapsulated FVPTC were reexamined for possible NIFTP reclassification. Of these, 1 case was reclassified as NIFTP, 1 case was upgraded to infiltrative FVPTC, and 1 was considered to be insufficient for NIFTP reclassification due to inadequate sampling of the capsule and nodule. Therefore, the Original Article percentage of malignant resection cases after NIFTP reclassification was 334 of 337 cases for the PFM diagnoses (ROM, 99.1%).
For the SFM cases with correlation before reclassification, 103 cases (ROM, 75.2%) demonstrated a malignant resection outcome ( Table 2 ). The 34 cases with a benign outcome were 4 cases of follicular adenoma, 4 cases of oncocytic cell adenoma, and 26 cases of nodular hyperplasia. Of the 137 SFM cases, 20 cases of noninvasive encapsulated FVPTC were identified and reexamined. Ten of these cases were reclassified as NIFTP, 4 cases were upgraded to other carcinomas (3 cases of classic PTC and 1 case of invasive encapsulated FVPTC), and 6 were considered insufficient for NIFTP reclassification due to inadequate sampling (Fig. 2) . The percentage of malignant resection cases after NIFTP reclassification was 87 of 131 for the SFM cases (ROM, 66.4%; the denominator was reduced by 6 insufficient cases).
The decreases in the ROM after NIFTP reclassification for the PFM cases (from 99.4% to 99.1%) and the SFM cases (from 75.2% to 66.4%) were not statistically significant (P 5 .6861 and P 5 .1389, respectively). However, if the 6 noninvasive encapsulated FVPTC cases that were insufficient for NIFTP reclassification had remained in the pool of nonmalignant cases, the ROM for the SFM category would have been 63.5% and the drop in the ROM would have been statistically significant (P 5 .0490).
The results of the survey of the diagnostic criteria requirements by the cytopathologists in the current study demonstrated that the vast majority required the same 5 of the 6 listed BSRTC criteria to make a definitive diagnosis of PFM/PTC (Table 3) . Blind review of random PFM and SFM cases by one of the authors (N.P.O.) demonstrated that the only criterion that discriminated PFM from SFM cases was the presence of 3 intranuclear pseudoinclusions (P 5 .0012). Although the majority of PFM cases (15 of 20 cases) demonstrated 3 intranuclear pseudoinclusions, 5 cases did not demonstrate this feature. Review of these 5 cases revealed additional details that explained the absence of this criterion. In one case, the malignancy was a sarcoma, and therefore the presence or absence of pseudoinclusions was not relevant. In another case, the cytopathologist was aware of metastatic PTC to a neck lymph node sampled previously at an outside institution. The third case was that of PTC recurrence in an area of previous surgery. The last 2 cases demonstrated borderline structures that were interpreted as rare or poorly formed intranuclear pseudoinclusions by the original pathologist but not by the reviewer.
We next correlated the histopathologic and molecular profiles of the PFM and SFM cases. The PFM cases (305 of 338 cases; 90.2%) had a significantly larger percentage of outcome cases with the typical overt nuclear features of PTC (classic PTC, tall cell variant of PTC, Warthin-like variant of PTC, solid variant of PTC, and cribriform morular variant of PTC) compared with the SFM cases (68 of 139 cases; 48.9%) (P<.0001). Of the 216 PFM cases with adequate materials for molecular testing, 146 were positive for the BRAF V600E mutation, 8 were positive for RET/ Original Article PTC gene fusion, and 3 were positive for RAS mutation.
Of the 106 SFM cases with adequate materials for molecular testing, 32 were positive for the BRAF V600E mutation, 2 were positive for RET/PTC gene fusion, 20 were positive for RAS mutation, and 1 was positive for PAX8/PPARy gene fusion (Table 4) . The "BRAF V600E-like" (BRAF V600E and RET/PTC) mutations were observed more often in the PFM cases compared with the SFM cases (71.3% vs 32.1%) (P<.0001). Conversely, the "RAS-like" (RAS, PAX8/PPARy, and BRAF K601E) mutations were more commonly noted in the SFM cases compared with the PFM cases (19.8% vs 1.4%) (P<.0001). After consideration for NIFTP reclassification, the 1 PFM case for which the resection outcome was reclassified from noninvasive encapsulated FVPTC to infiltrative FVPTC was found to have a BRAF V600E mutation. The 4 SFM cases for which the resection outcome was upgraded from noninvasive encapsulated FVPTC to other carcinomas demonstrated the following histologic and molecular results: 3 classic PTCs (BRAF V600E, NRAS, and an indeterminate molecular result) and 1 invasive encapsulated FVPTC (BRAF V600E). The molecular profiles of the 11 reclassified NIFTP cases were as follows: 2 NRAS, 2 HRAS, and 1 KRAS as well as 5 cases that demonstrated negative results using the 7-gene panel and 1 case that was found to be negative by next-generation sequencing (Table 4) .
DISCUSSION
Cytopathologically, the distinction between a diagnosis of SFM and one of PFM can be challenging and the decision to choose one over another may be influenced by a variety of factors. In contrast to surgical pathology cases, cytology specimens do not exhibit direct evidence of invasion (although in some organ systems, invasion may be suggested by the identification of necrosis or diathesis). Therefore, the cytologic diagnosis of malignancy is based primarily on microscopic features of the individual lesional cells, especially the nuclear features with or without overall architectural information. Furthermore, the cytologic diagnosis of thyroid malignancies, in particular PTC, has been complicated by the evolution in our understanding of this neoplasm.
In the 1950s and 1960s, the surgical pathology diagnosis of papillary carcinoma was based primarily on papillary architecture and the associated nuclear features. 13 To the best of our knowledge, Lindsay was the first to recognize the association between a follicular growth pattern and the presence of the nuclear features of PTC in some cases and introduced the term FVPTC. 14 Further study by
Chen and Rosai in 1977 popularized the term "FVPTC," which started to gain acceptance. 15 In the 1980s, more emphasis began to be placed on the nuclear features rather than architectural features for the diagnosis of PTC. In this setting, a subset of FVPTC was recognized: those with "papillary" nuclear features, a follicular growth pattern, and encapsulation. Some of these cases were reported to demonstrate metastasis, thereby justifying the categorization of "carcinoma." 16 However, the minimal threshold for the acceptance of "papillary" nuclear features and the histologic sampling protocol for these neoplasms (in particular capsular sampling) were challenging to establish. Not surprisingly, much interobserver variability among domestic and international thyroid pathology experts was documented with regard to these features. [17] [18] [19] In the most recent decade, significant attention has been given to the group of encapsulated FVPTCs that were shown to be more similar to follicular adenomas and minimally invasive follicular carcinomas, depending on the presence or absence of capsular and/or vascular invasion. 20, 21 Moreover, the nuclear features in these cases were particularly subtle (nuclear enlargement, membrane irregularities, and chromatin clearing with rare or absent pseudoinclusions), and could be present only focally within a nodule (sprinkle sign). The evolution in our understanding of PTC has influenced cytopathology practice. Cytology samples of PTCs such as the classic type, tall cell variant, Warthin-like variant, solid variant, and cribriform morular variant often demonstrate robust cytologic features of PTC (in particular nuclear grooves and 3 intranuclear pseudoinclusions). In contrast, samples from FVPTCs demonstrate a microfollicular growth pattern with varying degrees of nuclear alterations (nuclear enlargement, membrane irregularities, and chromatin clearing). If the latter nuclear alterations associated with FVPTC are abundantly present in cytology samples, an accurate presurgical diagnosis of PFM/PTC may be rendered. Conversely, when these nuclear alterations are found in few cells, the specificity for malignancy also decreases because these alterations are observed in benign reactive conditions. In the explanatory notes on FVPTC, the BSRTC atlas states "current practice suggests that only the cases with definitive nuclear features of PTC should be diagnosed unequivocally on FNA." 4 With the inception of NIFTP, the interpretation of "papillary-like nuclear features" (ie, nuclear enlargement, membrane irregularities, and chromatin clearing without pseudoinclusions) on cytology specimens has become a concern in diagnostic practice. Because the threshold for making a cytopathologic PFM diagnosis lies in the balance between the sensitivity to diagnose low-grade PTCs such as FVPTC and the specificity to minimize the risk of a false-positive diagnosis, the focus has shifted toward the interpretation of "definitive nuclear features." The main finding from the current study was that, for PFM cases, we experienced no significant drop in the ROM after NIFTP reclassification (from 99.4% to 99.1%), in contrast to the SFM cases, which demonstrated a more substantial decrease (from 75.5% to 66.9%). The drop in ROM for the SFM cases was in keeping with findings in comparable studies that were performed before the landmark NIFTP publication. 2, 3 By examining the PFM and SFM groups closely, we found that the histopathologic distribution in the PFM cases in the current study was different from that of the SFM cases. The histopathologic outcome for the PFM cases was predominantly PTC (320 of 338 cases; 94.7%). By far, classic PTC was the most common PTC type (263 of 320 cases; 82.2%) followed by the tall cell, Warthin-like, solid, and cribriform morular variants of PTC. In contrast, FVPTC was an infrequent outcome among the PFM cases before reclassification (11 of 338 cases; 3.3%). Furthermore, only 3 of these cases were noninvasive encapsulated FVPTC (only 1 of which qualified as NIFTP after reclassification). Therefore, the presurgical PFM diagnoses were associated strongly with PTC cases that demonstrated the typical overt PTC nuclear features (in particular intranuclear pseudoinclusions) and not with FVPTC or NIFTP. By comparison, the outcome for SFM cases included a much wider variety of lesions (PTCs, other malignant neoplasms, adenomas, and hyperplastic nodules). Because the cytologic criteria for the SFM diagnosis were less stringent, a FVPTC outcome comprised a substantial percentage of SFM cases (26 of 137 cases; 19.0%). Accordingly, 10 of the 11 reclassified NIFTP cases in the current study had a presurgical cytology diagnosis of SFM. Molecular correlation demonstrated that the PFM cases were associated strongly with the "BRAF V600E-like" mutations (BRAF V600E and RET/PTC) when compared with SFM cases (P<.0001). 22 This finding was in keeping with the fact that many of the surgical pathology correlates of PFM cases demonstrated the typical overt PTC nuclear features. Because the SFM cases had a mixed variety of surgical pathology outcomes, the molecular profiles were varied and "RAS-like" mutations (RAS, PAX8/PPARy, and BRAF K601E) were found more frequently in this group (Table 4) . Furthermore, our reclassified NIFTP cases demonstrated a RAS mutation in 5 of 11 cases (45.5%); no BRAF V600E-like mutation was found. These results were in line with the follicular-patterned morphology of the neoplasms and were comparable to the percentage of cases with RAS-like mutations (55.6%) in the landmark NIFTP study. 1 We attribute the maintenance of the high ROM in the PFM cases before and after NIFTP reclassification to 2 factors: our QA policy and the application of NIFTP criteria to the reexamined surgical pathology cases for reclassification. Our departmental QA committee regularly reviews all problematic cases, and these cases are discussed with the original pathologist. Emphasis is placed on minimizing false-positive diagnoses regardless of the organ site of origin. Under such QA scrutiny, over the last decade, we have become strict in our cytologic interpretive practice, requiring 5 of 6 BSRTC PTC criteria to make a PFM diagnosis. In particular, we have required the presence of nuclear grooves and 3 intranuclear pseudoinclusions along with other features. This approach, confirmed by our blinded study results, demonstrated that intranuclear pseudoinclusions were the key discriminating factor between PFM and SFM (P 5.0012). Based on the results of the current study, we believe that BSRTC criteria still are valid in the NIFTP era. Of course, this may depend on how rigorously the criteria are applied. Because NIFTP rarely demonstrates intranuclear pseudoinclusions, the possibility of overcalling an NIFTP case as PFM/PTC is very low when the first 5 BSRTC criteria are present in a given cytology case. In this regard, the current study results are similar to those of the recent study by Strickland et al that demonstrated that the drop in ROM after NIFTP reclassification would be <2% when the PFM/PTC diagnosis was reserved for cases that demonstrate at least papillary architecture, psammoma bodies, and/or pseudoinclusions. 2 Conversely, the majority of FVPTCs will not have a preceding PFM/PTC diagnosis if the first 5 BSRTC criteria are required. We also attribute the high ROM for the PFM diagnosis to the application of NIFTP criteria in the reexamined surgical pathology cases (Table 1) . 1 Although the previous literature often has used the terms "noninvasive encapsulated FVPTC" and "NIFTP" interchangeably, not all of the former qualify as NIFTP. In fact, the inclusion and exclusion criteria are elaborate and have been summarized further in a review by Thompson. 23 Specifically, features such as >1% true papillae formation, psammoma bodies, and the focal presence of other variants of PTC (eg, >30% solid, trabecular, or insular growth pattern) may have been overlooked in cases previously diagnosed as noninvasive encapsulated FVPTC before NIFTP inception. A recent study by Wong et al has shown that the delineation of NIFTP criteria has increased the rates of unfavorable histologic parameters in PTCs that do not qualify as NIFTP. 24 Moreover, a few implicit criteria regarding NIFTP are worth mentioning. First, oncocytic neoplasms were not included in the original NIFTP report and therefore were not part of the current study. Second, neoplasms measuring 1.0 cm may be noninvasive, encapsulated, and predominantly composed of an FVPTC pattern. However, all neoplasms in the original NIFTP study measured >1.0 cm and therefore we did not consider any neoplasm measuring 1.0 cm for NIFTP reclassification. Third, to fulfill the exclusion criteria, the entire capsule should be submitted for histologic examination. Overall, the inception of NIFTP has increased scrutiny in the processing and evaluation of follicular-patterned lesions.
The results of the current study demonstrated that a high ROM was maintained for the PFM cases before and after NIFTP reclassification. We attribute these findings to a strict QA policy and a departmental emphasis on minimizing the number of false-positive cases. To achieve this in practice, we have been requiring that cases meet 5 of 6 BSRTC criteria, in particular the presence of 3 intranuclear pseudoinclusions. We also reported herein that careful application of NIFTP criteria to the resected surgical pathology specimens is important so that the number of cases reclassified as NIFTP/nonmalignant is not inflated, thereby resulting in a lower ROM. Molecular correlations of the PFM cases in the current study demonstrated a strong association with BRAF V600E-like mutations. Conversely, the SFM cases, which harbored approximately 91% of reclassified NIFTPs, demonstrated a higher percentage of RAS-like mutations. Individual institutional ROM experiences may vary depending on parameters such as specimen processing and QA policies. In this regard, ongoing cytologic-histologic correlation exercises are valuable in determining the influence of NIFTP reclassification. The original BSRTC criteria for the diagnosis of PFM (in particular the presence of 3 intranuclear pseudoinclusions) are robust and valid in the NIFTP era. We agree with the editorial comment by LiVolsi et al that BSRTC diagnostic criteria should not be changed. 25 However, the use of criteria (eg, the number of criteria required) may vary from individual to individual. Because false-positive diagnoses are to be avoided, individual cytopathologists and institutions already may have started to adjust their practice patterns regarding the PFM/PTC diagnosis. 26 Multidisciplinary discussions among physicians and diagnosticians are important to develop a common understanding of this challenging area.
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